Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease.

Thumbnail
View / Open Files
Authors
Ritchie, Craig W
Russ, Tom C
Banerjee, Sube
Barber, Bob
Boaden, Andrew
Fox, Nick C
Holmes, Clive
Publication Date
2018-07-30
Journal Title
Alzheimers Res Ther
ISSN
1758-9193
Publisher
Springer Science and Business Media LLC
Type
Article
Metadata
Show full item record
Citation
Ritchie, C. W., Russ, T. C., Banerjee, S., Barber, B., Boaden, A., Fox, N. C., Holmes, C., et al. (2018). Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease.. Alzheimers Res Ther https://doi.org/10.1186/s13195-018-0372-0
Abstract
Since the publication of this article [1], it has come to the attention of the authors that information for one of the authors was not included in the competing interests section. Craig Richie has declared potential competing interests with the following companies; Janssen, Eisai, Pfizer, Eli Lilly, Roche Diagnostics, Boeringher Ingleheim, Novartis, AC Immune, Ixico, Aridhia, Amgen, Berry Consultants, Lundbeck, Sanofi, Quintiles (IQVIA) and Takeda. The full competing interests section for this article can be found below.
Keywords
1109 Neurosciences
Sponsorship
Medical Research Council (MR/L023784/2)
Medical Research Council (MR/L023784/1)
Identifiers
External DOI: https://doi.org/10.1186/s13195-018-0372-0
This record's URL: https://www.repository.cam.ac.uk/handle/1810/278555
Rights
All Rights Reserved
Rights Holder: The Author(s).
Licence URL: https://www.rioxx.net/licenses/all-rights-reserved/
Statistics



Total file downloads (since January 2020). For more information on metrics see the IRUS guide.